Pollan links psychedelics to loosening the brain's rigid self

1

Politics froze the science

The research blackout followed a political reaction to counterculture, not clinical proof that the molecules themselves were uniquely dangerous.

Pollan opens by noting his own cautious unfamiliarity with drugs he still associated with 1960s excess. He frames the puzzle as why serious scientists at Johns Hopkins, NYU, and Imperial College London had quietly restarted work on LSD and psilocybin after the 1970 Controlled Substances Act placed them in Schedule I.

That classification treated them as having no accepted medical use and high abuse potential, effectively freezing legitimate research for a generation. Rick Doblin’s MAPS, founded in 1986, began the slow rebuild one FDA step at a time.

Pollan treats the 2006 Johns Hopkins study led by Roland Griffiths as the real turning point. Thirty-six psychedelic-naive volunteers received psilocybin under controlled conditions; a majority ranked the experience among the most meaningful of their lives, on par with a child’s birth, and follow-ups showed the ratings held for months.

The same molecules that once triggered moral panic were re-entering psychiatry. Pollan argues the difference lay less in chemistry than in who administered them, under what conditions, and with what institutional backing.

In practice: The 2006 Griffiths study, run inside a rigorous academic setting rather than a commune, gave the field the foothold it had lacked since the 1960s.

2

Wonder outran sacred context

Western psychedelic culture began when a 1955 Mexican ceremony and a mass-magazine story handed powerful molecules to people with almost no responsible framework.

R. Gordon Wasson, a Wall Street executive and amateur ethnomycologist, joined a night-long velada in Huautla de Jiménez, Oaxaca, in 1955 under Mazatec curandera Maria Sabina. His 1957 Life magazine account introduced psilocybin mushrooms to a mass American audience.

Albert Hofmann, already known for the 1943 LSD self-experiment later called Bicycle Day, isolated and synthesized psilocybin from mushroom samples in 1958. Pollan presents the convergence as two unrelated discoveries—one accidental, one extractive—delivering potent tools without a culture of use.

Maria Sabina later said publicly that outsiders seeking recreation rather than ceremony degraded something sacred, and seekers overwhelmed Huautla through the 1960s. Pollan refuses to treat this as a minor footnote.

He reads it as the first turn of a pattern that recurs: awe at the substance’s effects repeatedly outruns any serious reckoning with the culture that first gave it meaning.

In practice: Maria Sabina’s later public regret and the tourist rush into Huautla show the extractive pattern Pollan tracks through the rest of the story.

3

Evangelism wrecked credibility

Timothy Leary’s shift from careful researcher to public slogan-maker did more damage to psychedelic science than any proven pharmacological danger.

The Harvard Psilocybin Project run by Leary and Richard Alpert from 1960 to 1962 began with real scientific ambition. Walter Pahnke’s 1962 Good Friday Experiment at Marsh Chapel gave divinity students psilocybin; a 1991 follow-up by Rick Doblin found most still called the experiences meaningful decades later.

The Concord Prison Experiment claimed reduced recidivism but was later shown to be methodologically weak. Even so, it fed a sense that the drugs might reshape behavior at scale.

Leary’s ambitions left the lab. Dismissed from Harvard in 1963, he embraced slogans such as “turn on, tune in, drop out” and became the symbol the establishment could cite as proof the drugs threatened social order.

Pollan argues the backlash was political, not primarily a response to clinical evidence of harm. Nixon’s 1970 scheduling decision cut funding for nearly forty years, forcing later researchers like Griffiths and Doblin to rebuild credibility by deliberately avoiding Leary’s rhetoric.

In practice: The Good Friday Experiment’s lasting personal meaning survived; Leary’s public evangelism did not, and the field paid for decades.

4

The entropic brain hypothesis

Psychedelics create their signature effects by suppressing the default mode network, loosening the brain’s top-down self-editor rather than through one simple chemical action.

Robin Carhart-Harris and colleagues at Imperial College London used fMRI in 2012 to show psilocybin decreases blood flow and activity in the default mode network. That network, including the medial prefrontal cortex and posterior cingulate cortex, runs hot during self-referential thought, rumination, and the sense of a continuous narrating self.

Pollan builds the “entropic brain” account around this finding. The ordinary brain acts as an efficient hierarchical prediction machine; the default mode network sits atop it as executive editor. Psychedelics disrupt that top-down control and raise neural entropy, letting normally separate networks talk in unusual combinations.

Subjectively this appears as synesthesia, a dissolving boundary between self and world, and the hyper-real quality common in trip reports. Researchers note parallels with EEG patterns in experienced meditators and with the exploratory cognition of young children, whose default mode networks are less developed.

Pollan uses the chapter to claim that the everyday psychological ego is not a fixed brain feature but an achievement of neural organization—one these drugs can temporarily undo.

In practice: The 2012 Imperial College fMRI work showed psilocybin quieting the very network that sustains the narrating self.

5

One session against death dread

A single guided high-dose psilocybin session can durably cut a dying patient’s fear of death, and the mystical intensity of the experience predicts benefit more than dose alone.

Parallel trials at NYU and Johns Hopkins, published together in 2016, gave one high dose of psilocybin to cancer patients with clinical depression and anxiety tied to their diagnoses. Patients wore eyeshades, heard curated music, and sat with two trained guides in a room furnished to feel nothing like a hospital.

Roughly 80 percent showed clinically significant reductions in depression and anxiety that held at six-month follow-up—an effect size unusual for any single-session psychiatric intervention. Patients often described the experience as more real than ordinary life and as an encounter outside personal identity that reframed mortality rather than distracting from it.

The strongest outcome predictor was not dose but intensity of the mystical-type experience, scored on a scale descended from Pahnke’s earlier work and asking about unity, sacredness, and transcendence of time and space.

Pollan reads the link back to the 1962 Good Friday markers as evidence that felt quality, not mere molecular exposure, is the therapeutic variable—and that preparation and setting may matter as much as the drug.

In practice: In the 2016 cancer trials, mystical-experience intensity, not milligrams alone, best predicted who still felt less anxiety six months later.

6

Disrupting rigid mental loops

Psychedelics may help addiction and depression by breaking one shared feature—cognitive rigidity—rather than treating three separate diseases with three separate actions.

Matthew Johnson’s 2014 Johns Hopkins pilot gave fifteen long-term smokers three psilocybin sessions plus cognitive behavioral therapy. At six months, about 80 percent remained abstinent, far above the roughly 35 percent success rate of the best conventional treatments, including varenicline.

A related NYU-led trial by Michael Bogenschutz found similar drops in heavy drinking after psilocybin-assisted sessions. Pollan ties both results to the entropic-brain story: addiction and depression can look like minds stuck in overly rigid predictive loops—craving circuits or rumination circuits.

Temporary disorder may let the brain settle into less entrenched patterns once the drug wears off. That model departs from chronic daily SSRIs, which manage transmitter levels without necessarily rewriting cognitive architecture.

Pollan notes the trials were small, poorly placebo-controlled, and narrow in population, yet he finds the mechanism coherent enough to explain why one class of experience might touch nicotine addiction, alcoholism, and treatment-resistant depression at once.

In practice: Johnson’s fifteen smokers reached about 80 percent six-month abstinence versus roughly 35 percent for top ordinary cessation aids.

7

The author’s own sessions

Pollan’s guided LSD, psilocybin, and 5-MeO-DMT journeys make the clinical findings vivid, yet one articulate journalist’s reports cannot replace controlled evidence.

Pollan arranges underground sessions through guides given only pseudonyms, because most of the work remains illegal outside trials. He tries a low-dose LSD session partly to test microdosing claims, a psilocybin journey in which personality felt like a temporary construction, and 5-MeO-DMT from Sonoran Desert toad venom that produced near-total obliteration of self-boundary.

He is candid about fear beforehand, disorientation during, and a weeks-long afterglow that softened defensiveness and heightened connection to the natural world. He also flags real risks of unsupervised use: without a stable setting and experienced sitter, intense experiences can leave lasting distress.

The chapter puts a voice on the earlier neuroscience and statistics. It remains inherently anecdotal—one health-privileged, self-selected subject reporting retrospectively under no regulatory oversight.

Pollan acknowledges the limit without fully resolving it: testimony bridges science and felt life, but it does not carry the weight of the clinical trials.

In practice: His psilocybin session left personality feeling almost arbitrary; the toad-venom session erased self-boundary almost completely.

8

Relearning childlike plasticity

Psychedelics may matter most by briefly returning the adult mind to the more plastic, less defended cognition of early childhood.

Pollan closes by linking default-mode neuroscience to mental development. Infant and young-child brains show weaker default-mode integration, matching the loosely associative, less filtered quality of early attention before the network matures into the efficient but rigid adult system.

He proposes that psychedelics offer a controlled, temporary reversal of that maturation. Adults briefly experience a mode of attention closer to a child’s, less burdened by entrenched expectations about self and world.

That frame gathers the earlier results—dying patients losing death fear, smokers dropping a decades-long habit, depressed patients escaping rumination—as variations on one shift: loosen the mind’s most rigid organizer and new patterns can take hold when ordinary consciousness returns.

Pollan is explicit that this implies a different psychiatric model built on occasional, carefully supported experiences rather than daily maintenance drugs. A coherent mechanism is not proof of safe scale, he cautions, yet the consistency across conditions justifies a serious second look.

In practice: Fear of death, nicotine craving, and depressive rumination all appear in his closing argument as rigid loops that ease when the adult predictive hierarchy briefly loosens.